Michael Hennig

2 ta ish

Neovii Biotech (Germany)

1. Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

   Michael Jäger, A. Schoberth, Peter Ruf +8

   Maqola20112 iqtibos

   ABIABI:AkademIndex/2026.other.913705

2. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

   Marion Ott, Frederik Marmé, Gerhard Moldenhauer +6

   Maqola20112 iqtibos

   ABIABI:AkademIndex/2026.other.913711